Perea S - Search Results

1

Invasive Aspergillus infections in hematologic malignancy patients.

Perea S, Patterson TF. Perea S, et al. Semin Respir Infect. 2002 Jun;17(2):99-105. doi: 10.1053/srin.2002.33443. Semin Respir Infect. 2002. PMID: 12070828 Review.

2

Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis.

Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Kirkpatrick WR, et al. Among authors: perea s. J Antimicrob Chemother. 2002 Feb;49(2):353-7. doi: 10.1093/jac/49.2.353. J Antimicrob Chemother. 2002. PMID: 11815579

3

Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.

Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Kirkpatrick WR, et al. Among authors: perea s. Antimicrob Agents Chemother. 2002 Aug;46(8):2564-8. doi: 10.1128/AAC.46.8.2564-2568.2002. Antimicrob Agents Chemother. 2002. PMID: 12121933 Free PMC article.

4

In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi MG, Patterson TF. Perea S, et al. Antimicrob Agents Chemother. 2002 Sep;46(9):3039-41. doi: 10.1128/AAC.46.9.3039-3041.2002. Antimicrob Agents Chemother. 2002. PMID: 12183266 Free PMC article.

5

Antifungal resistance in pathogenic fungi.

Perea S, Patterson TF. Perea S, et al. Clin Infect Dis. 2002 Nov 1;35(9):1073-80. doi: 10.1086/344058. Clin Infect Dis. 2002. PMID: 12384841

6

Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

Perea S, López-Ribot JL, Wickes BL, Kirkpatrick WR, Dib OP, Bachmann SP, Keller SM, Martinez M, Patterson TF. Perea S, et al. Antimicrob Agents Chemother. 2002 Jun;46(6):1695-703. doi: 10.1128/AAC.46.6.1695-1703.2002. Antimicrob Agents Chemother. 2002. PMID: 12019078 Free PMC article.

7

The C-terminal antibody binding domain of Candida albicans mp58 represents a protective epitope during candidiasis.

Viudes A, Lazzell A, Perea S, Kirkpatrick WR, Peman J, Patterson TF, Martinez JP, López-Ribot JL. Viudes A, et al. Among authors: perea s. FEMS Microbiol Lett. 2004 Mar 19;232(2):133-8. doi: 10.1016/S0378-1097(04)00042-4. FEMS Microbiol Lett. 2004. PMID: 15033231

8

Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients.

Lopez-Ribot JL, McAtee RK, Perea S, Kirkpatrick WR, Rinaldi MG, Patterson TF. Lopez-Ribot JL, et al. Among authors: perea s. Antimicrob Agents Chemother. 1999 Jul;43(7):1621-30. doi: 10.1128/AAC.43.7.1621. Antimicrob Agents Chemother. 1999. PMID: 10390213 Free PMC article.

9

Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients.

Perea S, López-Ribot JL, Kirkpatrick WR, McAtee RK, Santillán RA, Martínez M, Calabrese D, Sanglard D, Patterson TF. Perea S, et al. Antimicrob Agents Chemother. 2001 Oct;45(10):2676-84. doi: 10.1128/AAC.45.10.2676-2684.2001. Antimicrob Agents Chemother. 2001. PMID: 11557454 Free PMC article.

10

Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis.

Martínez M, López-Ribot JL, Kirkpatrick WR, Bachmann SP, Perea S, Ruesga MT, Patterson TF. Martínez M, et al. Among authors: perea s. J Antimicrob Chemother. 2002 Mar;49(3):515-24. doi: 10.1093/jac/49.3.515. J Antimicrob Chemother. 2002. PMID: 11864952

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

127 results

Search Page